Zobrazeno 1 - 10
of 22
pro vyhledávání: ''
Autor:
Jamie J. Shah, Francis Y. Lee, Bruce S. Fischer, Hossein Khiabanian, Sharon R. Pine, Joseph R. Bertino, Katherine M. Morgan, Amartya Singh, Jeffrey A. Rosenfeld
Publikováno v:
Molecular Cancer Therapeutics. 16:2759-2769
Notch signaling is aberrantly activated in approximately one third of non–small cell lung cancers (NSCLC). We characterized the interaction between BMS-906024, a clinically relevant Notch gamma secretase inhibitor, and front-line chemotherapy in pr
Autor:
Michele De Palma, Alan Guichard, Chiara Cianciaruso, Martina Schmittnaegel, Amaia Martinez-Usatorre, Ece Kadioglu, Sina Nassiri, Ioanna Keklikoglou, Bruno Torchia, Etienne Meylan, Carola Ries
Publikováno v:
Cancer Research. 81:75-75
Immune checkpoint blockade (ICB) with PD-1 or PD-L1 antibodies has been approved for the treatment of non-small cell lung cancer (NSCLC), often in combination with chemotherapy. However, only a minority of the patients respond and sustained remission
Autor:
Arina Riabinska, Miriam Rinneburger, Wenzel Vogel, Alexandra Florin, Mehmet Akyüz, Björn Schumacher, Reinhard Büttner, Christian Fritz, Sebastian Michels, Christiane Kümpers, Jürgen Thomale, David Maintz, Sven Perner, Mladen Jokic, Anne Offermann, Luka Ozretić, Maike Wittersheim, Thorsten Persigehl, Niklas Klümper, Anna Schmitt, Judith Eva Spiro, Michael Nowak, Martin Erkel, Hans Christian Reinhardt, Ignacija Vlasic, Jürgen Wolf, Daniela Welcker
Publikováno v:
Molecular Cancer Research. 14:1110-1123
KRAS-mutant lung adenocarcinoma is among the most common cancer entities and, in advanced stages, typically displays poor prognosis due to acquired resistance against chemotherapy, which is still largely based on cisplatin-containing combination regi
Autor:
Anne de la Rochefordière, Ivan Bièche, Virginie Fourchotte, Florence Joly, Emmanuel Sevin, Béatrice Weber, Mathieu Minsat, Benard Asselain, Anne Floquet, Maud Kamal, Suzy Scholl, Maud Aumont, Quentin Leroy, Laurence Thomas, Marius Pop, Alhassane Diallo, Sophie Maillard, Hervé Curé, Michel Fabbro, Peter Petrow, Philippe Beuzeboc, Thierry Petit, K. Peignaux, Laurence Gladieff, Corine Plancher, Laurence Gonzague, Virginie Bernard, Claire Brunaud, Christine Kerr, Dominique Berton-Rigaud, AnaTereza Nadan, Sebastien Armanet, Audrey Margogne
Publikováno v:
Clinical Cancer Research. 21:2530-2537
Purpose: EGFR is frequently overexpressed in cervical cancer, suggesting EGFR blockade as a promising treatment approach. Cetuximab, an anti EGFR antibody, used conjointly with radiochemotherapy, was feasible in first-line treatment of cervix carcino
Autor:
Randal May, Dongfeng Qu, Janani Panneerselvam, Courtney W. Houchen, Nathaniel Weygant, Naushad Ali, Michael S. Bronze, Chinthalapally V. Rao, Priyanga Mohandoss, Timothy C. Wang, Parthasarathy Chandrakesan
Publikováno v:
Cancer Research. 79:2119-2119
Background: Lung cancer is the deadliest cancer in both men and women. About 85% of lung cancers are non-small cell lung cancer (NSCLC) and almost 25% of all types of NSCLC contain KRAS mutations, which remain as an undruggable challenge. Doublecorti
Publikováno v:
Cancer Research. 75:B1-02
The purpose of this study is to correlate genetic mutations, amino-acid variants, signaling pathways with platiunum based drug activity to shed light on personalized treatment of cancer. Platinum anticancer drugs such as cisplatin, carboplatin, and o
Publikováno v:
Cancer Research. 77:1429-1429
Non-small cell lung cancer (NSCLC) treatment usually involves surgery and chemotherapy with tyrosine kinase inhibitors (TKI) in patients with EGFR mutations (10-15% in Western population, 40% in Asian populations) or with platinum-based regimens. Res
Publikováno v:
Clinical Cancer Research. 23:B01-B01
Background and Significance: The continuous expression of HPV oncogenes is responsible for initiating and driving cervical cancer. Current treatments include radiation and Cisplatin-based chemotherapy. Targeted therapies can be directed to specific s
Publikováno v:
Cancer Research. 76:1253-1253
Lung cancer remains the leading cause of cancer related mortality throughout the world, and is estimated to kill more than one million people this year. Mutations in KRAS occur in about 1/3 of all lung adenocarcinomas, the most common histologic subt
Autor:
Glenn McCluggage, Nuala McCabe, Alistair R.W. Williams, Niamh McGivern, Caroline O. Michie, Laura Hill, Andrena McGavigan, Michael Churchman, Charlie Gourley, Richard D. Kennedy, Karen Keating, Eamonn J. O'Brien, Denis Paul Harkin, Timothy Davison
Publikováno v:
Cancer Research. 76:453-453
Introduction We have previously defined 3 molecular subgroups of High grade serous ovarian cancer (HGSOC), ‘Angio’, ‘Immune’ and ‘Angio_immune’ subgroups using gene expression data from 265 FFPE HGSOC samples obtained from treatment naive